



PRESS RELEASE

FOR IMMEDIATE RELEASE

Nova MSC inks agreement with leading Japanese ophthalmic solution provider

- This collaboration will bring SELENA+ to Harmony's users in 18 countries in South and South East Asia

KUALA LUMPUR, 12th NOVEMBER 2020 – Nova MSC Berhad's ("Nova MSC" or "the Group") indirect subsidiary EyRIS Pte Ltd ("EyRIS") has inked an agreement with **Topcon Healthcare Solutions Asia Pacific** ("Topcon Healthcare") to bring its first **artificial intelligence** ("AI") based product – SELENA+ to Harmony's users in **18 countries** in South and South-East Asia.

Topcon Healthcare is a leading Japanese provider of medical devices and software solutions for the eye care community. It is reputed in the industry for their high-performance retinal imaging cameras and is one of the leading manufacturers in the world.

Harmony is an Eye Health Screening solution developed by Topcon Healthcare that enables screening sites to be linked with eye professionals in a seamless and efficient manner.

On the other hand, as a self-learning retinal screening technology, SELENA+ **cuts the time** needed to spot signs of diabetic eye diseases, namely: i) Diabetic Retinopathy ("DR"), ii) Glaucoma and iii) Age-Related Macular Degeneration ("AMD").

It was jointly developed by the Singapore Eye Research Institute ("SERI") and the National University of Singapore – School of Computing ("NUS-SoC"). SELENA+ is able to detect the retinal diseases in less than 2 minutes upon submission of the patient's fundus images.

EyRIS will appoint Topcon Healthcare to market and distribute SELENA+ directly or through its distribution network in 18 countries in the South and Southeast Asia (including Thailand, India and Hong Kong).

Nova MSC Berhad and EyRIS Group Chief Executive Officer Mr Lai Teik Kin said: "We are deeply humbled by Topcon Healthcare's decision to partnering EyRIS. It is affirmative of

confidence in our product and the team of clinician & technology researchers behind the product. We look forward to a fruitful working relationship with Topcon Healthcare in the years to come.”

Managing Director of Topcon Healthcare Solution Asia Pacific Mr Leo Hiroshi Nagatake said: “Topcon is extremely excited to be able to work with EyRIS in Asian countries. We firmly believe the current situation of eye health to the next stage by having our innovative products put together.”

The Company said with the changing diet and lifestyle, the prevalence of diabetes is growing at an alarming rate in Asia. Consequently, there is a correlated rise in diabetic-related blindness which can be prevented through early detection and treatment. This collaboration underlines the synergies that can be harnessed to pursue a shared vision of creating awareness of the importance for annual screening and making quality eye care more accessible to all.

Issued by: Aegis Communication on behalf of **Nova MSC Berhad**
Date: 12th November 2020
For further media enquires please contact:

Jason Fong
Tel: +6012 952 0015
Email: jason@aegiscomm.com.my


We are Nova MSC Berhad

Established in 2002, Nova MSC Bhd is a Bursa Malaysia ACE Market-listed company, which is involved in four main business pillars namely, healthcare, Digital Government, building automation and virtual construction. We are a leading provider of ready-to-deploy, industry-focused application software and services for both the public and healthcare sectors, with an international track-record. Our products are developed based on our technical knowledge and in-depth understanding of industry demands and the clients' requirements, thereby bringing improved productivity to our customers.

For more info, visit: <http://www.nova-hub.com/>

About SELENA+

Early screening is highly effective in helping to prevent blindness from a range of eye diseases. SELENA+ is an intelligent deep learning system that can detect eye diseases: this system was jointly invented by researchers at NUS School of Computing (NUS-SoC) and the Singapore Eye Research Institute (SERI) to perform automated image analysis of retinal images. The analysis results will be used to provide early detection of eye diseases, including diabetic retinopathy (DR), glaucoma and age-related macular degeneration (AMD).



About Topcon Healthcare

Topcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever- changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multimodal imaging, vendor-neutral data management and ground- breaking remote diagnostic technology.

A globally-oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.

Forward-Looking Statements

The statement included in this press release, other than statements of historical facts, are forward-looking statements. Forward-looking statement generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “plan,” “seek,” or “believe.” These forward-looking statements, which are subject to risks, uncertainties, and assumptions, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations about future event. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statement, including, but not limited to our ability to win additional business. Although we believe the expectations reflected in the forward- looking statements are reasonable, we cannot guarantee future result, level of activity, performance, or achievements. You should not rely upon forward- looking statements as predictions of future events. These forward-looking statements apply only as of the date of this press release; as such, they should not be unduly relied upon as circumstances change. Except as required by law, we are not obligated, and we undertake no obligation, to release publicly any revisions to these forward-looking statements that might reflect events or circumstances occurring after the date of this release or those that might reflect the occurrence of unanticipated events.